Contrasting disease and nondisease protein aggregation by molecular simulation

Nicolas Lux Fawzi, Eng Hui Yap, Yuka Okabe, Kevin L. Kohlstedt, Scott P. Brown, Teresa Head-Gordon

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

(Figure Presented) Protein aggregation can be defined as the sacrifice of stabilizing intrachain contacts of the functional state that are replaced with interchain contacts to form non-functional states. The resulting aggregate morphologies range from amorphous structures without long-range order typical of nondisease proteins involved in inclusion bodies to highly structured fibril assemblies typical of amyloid disease proteins. In this Account, we describe the development and application of computational models for the investigation of nondisease and disease protein aggregation as illustrated for the proteins L and G and the Alzheimer's Aβ systems. In each case, we validate the models against relevant experimental observables and then expand on the experimen tal window to better elucidate the link between molecular properties and aggregation outcomes. Our studies show that each dass of protein exhibits distinct aggregation mechanisms that are dependent on protein sequence, protein concentration, and solution conditions. Nondisease proteins can have native structural elements in the denatured state ensemble or rapidly form early folding intermediates, which offers avenues of protection against aggregation even at relatively high concentrations. The possibility that early folding intermediates may be evolutionarily selected for their protective role against unwanted aggregation could be a useful strategy for reengineering sequences to slow aggregation and increase folding yield in industrial protein production. The observed oligomeric aggregates that we see for nondisease proteins L and G may represent the nuclei for larger aggregates, not just for large amorphous inclusion bodies, but potentially as the seeds of ordered fibrillar aggregates, since most nondisease proteins can form amyloid fibrils under conditions that destabilize the native state. By contrast, amyloidogenic protein sequences such as Aβ1-40,42 and the familial Alzheimer's disease (FAD) mutants favor aggregation into ordered fibrils once the free-energy barrier for forming a critical nucleus is crossed. However, the structural characteristics and oligomer size of the soluble nucleation species have yet to be determined experimentally for any disease peptide sequence, and the molecular mechanism of polymerization that eventually delineates a mature fibril is unknown. This is in part due to the limited experimental access to very low peptide concentrations that are required to characterize these early aggregation events, providing an opportunity for theoretical studies to bridge the gap between the monomer and fibril end points and to develop testable hypotheses. Our model shows that Aβ1-40 requires as few as 6-10 monomer chains (depending on sequence) to begin manifesting the cross-β order that is a signature of formation of amyloid filaments or fibrils assessed in dye-binding kinetic assays. The richness of the oligomeric structures and viable filament and fibril polymorphs that we observe may offer structural clues to disease virulence variations that are seen for the WT and hereditary mutants.

Original languageEnglish (US)
Pages (from-to)1037-1047
Number of pages11
JournalAccounts of Chemical Research
Volume41
Issue number8
DOIs
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Agglomeration
Proteins
Amyloid
Monomers
Amyloidogenic Proteins
Reengineering
Peptides
Energy barriers
Polymorphism
Oligomers
Free energy
Seed
Assays
Nucleation
Coloring Agents
Polymerization
Kinetics

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Fawzi, N. L., Yap, E. H., Okabe, Y., Kohlstedt, K. L., Brown, S. P., & Head-Gordon, T. (2008). Contrasting disease and nondisease protein aggregation by molecular simulation. Accounts of Chemical Research, 41(8), 1037-1047. https://doi.org/10.1021/ar800062k

Contrasting disease and nondisease protein aggregation by molecular simulation. / Fawzi, Nicolas Lux; Yap, Eng Hui; Okabe, Yuka; Kohlstedt, Kevin L.; Brown, Scott P.; Head-Gordon, Teresa.

In: Accounts of Chemical Research, Vol. 41, No. 8, 08.2008, p. 1037-1047.

Research output: Contribution to journalArticle

Fawzi, NL, Yap, EH, Okabe, Y, Kohlstedt, KL, Brown, SP & Head-Gordon, T 2008, 'Contrasting disease and nondisease protein aggregation by molecular simulation', Accounts of Chemical Research, vol. 41, no. 8, pp. 1037-1047. https://doi.org/10.1021/ar800062k
Fawzi NL, Yap EH, Okabe Y, Kohlstedt KL, Brown SP, Head-Gordon T. Contrasting disease and nondisease protein aggregation by molecular simulation. Accounts of Chemical Research. 2008 Aug;41(8):1037-1047. https://doi.org/10.1021/ar800062k
Fawzi, Nicolas Lux ; Yap, Eng Hui ; Okabe, Yuka ; Kohlstedt, Kevin L. ; Brown, Scott P. ; Head-Gordon, Teresa. / Contrasting disease and nondisease protein aggregation by molecular simulation. In: Accounts of Chemical Research. 2008 ; Vol. 41, No. 8. pp. 1037-1047.
@article{4061412d236c41fe885ba1d31f880f39,
title = "Contrasting disease and nondisease protein aggregation by molecular simulation",
abstract = "(Figure Presented) Protein aggregation can be defined as the sacrifice of stabilizing intrachain contacts of the functional state that are replaced with interchain contacts to form non-functional states. The resulting aggregate morphologies range from amorphous structures without long-range order typical of nondisease proteins involved in inclusion bodies to highly structured fibril assemblies typical of amyloid disease proteins. In this Account, we describe the development and application of computational models for the investigation of nondisease and disease protein aggregation as illustrated for the proteins L and G and the Alzheimer's Aβ systems. In each case, we validate the models against relevant experimental observables and then expand on the experimen tal window to better elucidate the link between molecular properties and aggregation outcomes. Our studies show that each dass of protein exhibits distinct aggregation mechanisms that are dependent on protein sequence, protein concentration, and solution conditions. Nondisease proteins can have native structural elements in the denatured state ensemble or rapidly form early folding intermediates, which offers avenues of protection against aggregation even at relatively high concentrations. The possibility that early folding intermediates may be evolutionarily selected for their protective role against unwanted aggregation could be a useful strategy for reengineering sequences to slow aggregation and increase folding yield in industrial protein production. The observed oligomeric aggregates that we see for nondisease proteins L and G may represent the nuclei for larger aggregates, not just for large amorphous inclusion bodies, but potentially as the seeds of ordered fibrillar aggregates, since most nondisease proteins can form amyloid fibrils under conditions that destabilize the native state. By contrast, amyloidogenic protein sequences such as Aβ1-40,42 and the familial Alzheimer's disease (FAD) mutants favor aggregation into ordered fibrils once the free-energy barrier for forming a critical nucleus is crossed. However, the structural characteristics and oligomer size of the soluble nucleation species have yet to be determined experimentally for any disease peptide sequence, and the molecular mechanism of polymerization that eventually delineates a mature fibril is unknown. This is in part due to the limited experimental access to very low peptide concentrations that are required to characterize these early aggregation events, providing an opportunity for theoretical studies to bridge the gap between the monomer and fibril end points and to develop testable hypotheses. Our model shows that Aβ1-40 requires as few as 6-10 monomer chains (depending on sequence) to begin manifesting the cross-β order that is a signature of formation of amyloid filaments or fibrils assessed in dye-binding kinetic assays. The richness of the oligomeric structures and viable filament and fibril polymorphs that we observe may offer structural clues to disease virulence variations that are seen for the WT and hereditary mutants.",
author = "Fawzi, {Nicolas Lux} and Yap, {Eng Hui} and Yuka Okabe and Kohlstedt, {Kevin L.} and Brown, {Scott P.} and Teresa Head-Gordon",
year = "2008",
month = "8",
doi = "10.1021/ar800062k",
language = "English (US)",
volume = "41",
pages = "1037--1047",
journal = "Accounts of Chemical Research",
issn = "0001-4842",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Contrasting disease and nondisease protein aggregation by molecular simulation

AU - Fawzi, Nicolas Lux

AU - Yap, Eng Hui

AU - Okabe, Yuka

AU - Kohlstedt, Kevin L.

AU - Brown, Scott P.

AU - Head-Gordon, Teresa

PY - 2008/8

Y1 - 2008/8

N2 - (Figure Presented) Protein aggregation can be defined as the sacrifice of stabilizing intrachain contacts of the functional state that are replaced with interchain contacts to form non-functional states. The resulting aggregate morphologies range from amorphous structures without long-range order typical of nondisease proteins involved in inclusion bodies to highly structured fibril assemblies typical of amyloid disease proteins. In this Account, we describe the development and application of computational models for the investigation of nondisease and disease protein aggregation as illustrated for the proteins L and G and the Alzheimer's Aβ systems. In each case, we validate the models against relevant experimental observables and then expand on the experimen tal window to better elucidate the link between molecular properties and aggregation outcomes. Our studies show that each dass of protein exhibits distinct aggregation mechanisms that are dependent on protein sequence, protein concentration, and solution conditions. Nondisease proteins can have native structural elements in the denatured state ensemble or rapidly form early folding intermediates, which offers avenues of protection against aggregation even at relatively high concentrations. The possibility that early folding intermediates may be evolutionarily selected for their protective role against unwanted aggregation could be a useful strategy for reengineering sequences to slow aggregation and increase folding yield in industrial protein production. The observed oligomeric aggregates that we see for nondisease proteins L and G may represent the nuclei for larger aggregates, not just for large amorphous inclusion bodies, but potentially as the seeds of ordered fibrillar aggregates, since most nondisease proteins can form amyloid fibrils under conditions that destabilize the native state. By contrast, amyloidogenic protein sequences such as Aβ1-40,42 and the familial Alzheimer's disease (FAD) mutants favor aggregation into ordered fibrils once the free-energy barrier for forming a critical nucleus is crossed. However, the structural characteristics and oligomer size of the soluble nucleation species have yet to be determined experimentally for any disease peptide sequence, and the molecular mechanism of polymerization that eventually delineates a mature fibril is unknown. This is in part due to the limited experimental access to very low peptide concentrations that are required to characterize these early aggregation events, providing an opportunity for theoretical studies to bridge the gap between the monomer and fibril end points and to develop testable hypotheses. Our model shows that Aβ1-40 requires as few as 6-10 monomer chains (depending on sequence) to begin manifesting the cross-β order that is a signature of formation of amyloid filaments or fibrils assessed in dye-binding kinetic assays. The richness of the oligomeric structures and viable filament and fibril polymorphs that we observe may offer structural clues to disease virulence variations that are seen for the WT and hereditary mutants.

AB - (Figure Presented) Protein aggregation can be defined as the sacrifice of stabilizing intrachain contacts of the functional state that are replaced with interchain contacts to form non-functional states. The resulting aggregate morphologies range from amorphous structures without long-range order typical of nondisease proteins involved in inclusion bodies to highly structured fibril assemblies typical of amyloid disease proteins. In this Account, we describe the development and application of computational models for the investigation of nondisease and disease protein aggregation as illustrated for the proteins L and G and the Alzheimer's Aβ systems. In each case, we validate the models against relevant experimental observables and then expand on the experimen tal window to better elucidate the link between molecular properties and aggregation outcomes. Our studies show that each dass of protein exhibits distinct aggregation mechanisms that are dependent on protein sequence, protein concentration, and solution conditions. Nondisease proteins can have native structural elements in the denatured state ensemble or rapidly form early folding intermediates, which offers avenues of protection against aggregation even at relatively high concentrations. The possibility that early folding intermediates may be evolutionarily selected for their protective role against unwanted aggregation could be a useful strategy for reengineering sequences to slow aggregation and increase folding yield in industrial protein production. The observed oligomeric aggregates that we see for nondisease proteins L and G may represent the nuclei for larger aggregates, not just for large amorphous inclusion bodies, but potentially as the seeds of ordered fibrillar aggregates, since most nondisease proteins can form amyloid fibrils under conditions that destabilize the native state. By contrast, amyloidogenic protein sequences such as Aβ1-40,42 and the familial Alzheimer's disease (FAD) mutants favor aggregation into ordered fibrils once the free-energy barrier for forming a critical nucleus is crossed. However, the structural characteristics and oligomer size of the soluble nucleation species have yet to be determined experimentally for any disease peptide sequence, and the molecular mechanism of polymerization that eventually delineates a mature fibril is unknown. This is in part due to the limited experimental access to very low peptide concentrations that are required to characterize these early aggregation events, providing an opportunity for theoretical studies to bridge the gap between the monomer and fibril end points and to develop testable hypotheses. Our model shows that Aβ1-40 requires as few as 6-10 monomer chains (depending on sequence) to begin manifesting the cross-β order that is a signature of formation of amyloid filaments or fibrils assessed in dye-binding kinetic assays. The richness of the oligomeric structures and viable filament and fibril polymorphs that we observe may offer structural clues to disease virulence variations that are seen for the WT and hereditary mutants.

UR - http://www.scopus.com/inward/record.url?scp=51649109850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649109850&partnerID=8YFLogxK

U2 - 10.1021/ar800062k

DO - 10.1021/ar800062k

M3 - Article

C2 - 18646868

AN - SCOPUS:51649109850

VL - 41

SP - 1037

EP - 1047

JO - Accounts of Chemical Research

JF - Accounts of Chemical Research

SN - 0001-4842

IS - 8

ER -